Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen-Cilag’s PE drug authorised for marketing

Janssen-Cilag’s PE drug authorised for marketing

11th March 2009

Janssen-Cilag has received marketing authorisation in Finland and Sweden for the first ever oral prescription medication for premature ejaculation (PE).

Named Priligy (Dapoxetine), it is an on-demand treatment for men aged 18 to 64 with the condition.

Professor Hartmut Porst, from the Private Institute for Urology and Andrology in Hamburg, remarked it is an important new drug for doctors and patients alike.

Until now, there has been a deficiency in the diagnosis and treatment of the problem due to the lack of previously approved oral medication for it, he explained.

“For the first time, physicians will be able to provide men with a pharmaceutical product that has been specifically developed for PE and that is proven to be effective,” he commented.

Finland and Sweden are the first countries worldwide to grant marketing approval for the compound. National authorisation and licenses are expected to follow during April this year in Austria, Germany, Spain, Italy and Portugal.

Janssen-Cilag is part of the Johnson & Johnson group. It develops and markets treatments for pain management, oncology, central nervous system disorders, infectious diseases, gastrointestinal disorders and reproductive health.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.